Evidence map›Paper›PMID 41381241›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Targeted β

Julia G Fricke, Frida Westerbergh, Lisa McDougall, Chiara Favaretto, Emanuel Christ, Guillaume P Nicolas, Susanne Geistlich, David E Schmid, Francesca Borgna, Melpomeni Fani and 5 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Julia G FrickeDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Frida WesterberghDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Lisa McDougallDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Chiara FavarettoDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Emanuel ChristENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.
Guillaume P NicolasDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Susanne GeistlichCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
David E SchmidCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
Francesca BorgnaCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
Melpomeni FaniDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Peter BernhardtDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Nicholas P van der MeulenCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
Cristina MüllerCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
Roger SchibliCenter for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland.
Damian WildDivision of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this phase 0 study was to determine the absorbed doses in tumors and relevant organs after a test injection of [

Indexed as

Beta ParticlesElectronsIntestinal NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsPancreatic NeoplasmsReceptors, SomatostatinStomach NeoplasmsAdultAgedFemaleHumansIsotope LabelingMaleMiddle AgedOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Somatostatin161TbDOTA-LM3DOTATOCgastroenteropancreatic neuroendocrine tumorspeptide receptor radionuclide therapy

Identifiers

PMID41381241
PMCPMC12955530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.